Literature DB >> 28218255

Approvals in 2016: the march of the checkpoint inhibitors.

Gideon M Blumenthal1, Richard Pazdur1.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28218255     DOI： 10.1038/nrclinonc.2017.15

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  8 in total

1.  Next-Generation Sequencing in Oncology in the Era of Precision Medicine.

Authors:  Gideon M Blumenthal; Elizabeth Mansfield; Richard Pazdur
Journal:  JAMA Oncol       Date:  2016-01       Impact factor: 31.777

2.  Response Rate as an Approval End Point in Oncology: Back to the Future.

Authors:  Gideon M Blumenthal; Richard Pazdur
Journal:  JAMA Oncol       Date:  2016-06-01       Impact factor: 31.777

3.  Real-World Evidence - What Is It and What Can It Tell Us?

Authors:  Rachel E Sherman; Steven A Anderson; Gerald J Dal Pan; Gerry W Gray; Thomas Gross; Nina L Hunter; Lisa LaVange; Danica Marinac-Dabic; Peter W Marks; Melissa A Robb; Jeffrey Shuren; Robert Temple; Janet Woodcock; Lilly Q Yue; Robert M Califf
Journal:  N Engl J Med       Date:  2016-12-08       Impact factor: 91.245

4.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

5.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

Authors:  Jonathan E Rosenberg; Jean Hoffman-Censits; Tom Powles; Michiel S van der Heijden; Arjun V Balar; Andrea Necchi; Nancy Dawson; Peter H O'Donnell; Ani Balmanoukian; Yohann Loriot; Sandy Srinivas; Margitta M Retz; Petros Grivas; Richard W Joseph; Matthew D Galsky; Mark T Fleming; Daniel P Petrylak; Jose Luis Perez-Gracia; Howard A Burris; Daniel Castellano; Christina Canil; Joaquim Bellmunt; Dean Bajorin; Dorothee Nickles; Richard Bourgon; Garrett M Frampton; Na Cui; Sanjeev Mariathasan; Oyewale Abidoye; Gregg D Fine; Robert Dreicer
Journal:  Lancet       Date:  2016-03-04       Impact factor: 79.321

6.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

Authors:  Andrew W Roberts; Matthew S Davids; John M Pagel; Brad S Kahl; Soham D Puvvada; John F Gerecitano; Thomas J Kipps; Mary Ann Anderson; Jennifer R Brown; Lori Gressick; Shekman Wong; Martin Dunbar; Ming Zhu; Monali B Desai; Elisa Cerri; Sari Heitner Enschede; Rod A Humerickhouse; William G Wierda; John F Seymour
Journal:  N Engl J Med       Date:  2015-12-06       Impact factor: 91.245

7.  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

Authors:  Robert L Ferris; George Blumenschein; Jerome Fayette; Joel Guigay; A Dimitrios Colevas; Lisa Licitra; Kevin Harrington; Stefan Kasper; Everett E Vokes; Caroline Even; Francis Worden; Nabil F Saba; Lara C Iglesias Docampo; Robert Haddad; Tamara Rordorf; Naomi Kiyota; Makoto Tahara; Manish Monga; Mark Lynch; William J Geese; Justin Kopit; James W Shaw; Maura L Gillison
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

8.  Benefit-Risk Summary of Crizotinib for the Treatment of Patients With ROS1 Alteration-Positive, Metastatic Non-Small Cell Lung Cancer.

Authors:  Dickran Kazandjian; Gideon M Blumenthal; Lola Luo; Kun He; Ingrid Fran; Steven Lemery; Richard Pazdur
Journal:  Oncologist       Date:  2016-06-21
  8 in total
  6 in total

1.  Patent trend and competitive analysis of cancer immunotherapy in the United States.

Authors:  Chia-Lin Pan; Feng-Chi Chen
Journal:  Hum Vaccin Immunother       Date:  2017-11-02       Impact factor: 3.452

Review 2.  Cancer Immunotherapies: Are They as Effective in the Elderly?

Authors:  Kate Poropatich; Joel Fontanarosa; Sandeep Samant; Jeffrey A Sosman; Bin Zhang
Journal:  Drugs Aging       Date:  2017-08       Impact factor: 4.271

3.  Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy.

Authors:  Yulian Khagi; Aaron M Goodman; Gregory A Daniels; Sandip P Patel; Assuntina G Sacco; James M Randall; Lyudmila A Bazhenova; Razelle Kurzrock
Journal:  Clin Cancer Res       Date:  2017-10-01       Impact factor: 12.531

Review 4.  A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab.

Authors:  Petros Fessas; Hassal Lee; Shinji Ikemizu; Tobias Janowitz
Journal:  Semin Oncol       Date:  2017-07-04       Impact factor: 4.929

5.  Network Analysis of Drug-target Interactions: A Study on FDA-approved New Molecular Entities Between 2000 to 2015.

Authors:  Hui-Heng Lin; Le-Le Zhang; Ru Yan; Jin-Jian Lu; Yuanjia Hu
Journal:  Sci Rep       Date:  2017-09-25       Impact factor: 4.379

Review 6.  Checks and Balances in Autoimmune Vasculitis.

Authors:  Rebeca Hid Cadena; Wayel H Abdulahad; G A P Hospers; T T Wind; Annemieke M H Boots; Peter Heeringa; Elisabeth Brouwer
Journal:  Front Immunol       Date:  2018-02-22       Impact factor: 7.561
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.